[Newsletter] Vol 72. February 2026
This is Vol.72 Newsletter for February 2026. In this issue, we cover the approaching patent cliff driving a new wave of biosimilar competition, the regulator’s shift toward full-cycle support for rare disease drug development, and how Alzheimer’s R&D and dealmaking…